NCT04980664View on ClinicalTrials.gov

Effort to Narrow the Gap Between in Accordance With Guidelines and Consent to Treat CHB Population in East of China

NAUnknownINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

July 31, 2023

Conditions
Chronic Hepatitis b
Interventions
OTHER

Integrated intervention strategies

Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.

Trial Locations (4)

210008

Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing

213001

The Third People's Hospital of Changzhou, Changzhou

215000

The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou

223300

Huai'an No.4 People's Hospital, Huai'an

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

NCT04980664 - Effort to Narrow the Gap Between in Accordance With Guidelines and Consent to Treat CHB Population in East of China | Biotech Hunter | Biotech Hunter